EP2323679A4 - Clip-hemmer und verfahren zur modulierung der immunfunktion - Google Patents

Clip-hemmer und verfahren zur modulierung der immunfunktion

Info

Publication number
EP2323679A4
EP2323679A4 EP09800699A EP09800699A EP2323679A4 EP 2323679 A4 EP2323679 A4 EP 2323679A4 EP 09800699 A EP09800699 A EP 09800699A EP 09800699 A EP09800699 A EP 09800699A EP 2323679 A4 EP2323679 A4 EP 2323679A4
Authority
EP
European Patent Office
Prior art keywords
methods
immune function
modulating immune
clip inhibitors
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09800699A
Other languages
English (en)
French (fr)
Other versions
EP2323679A2 (de
Inventor
Martha Karen Newell
Evan Newell
Haig Keledjian
Michael Agadjanyan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VG Life Sciences Inc
University of Colorado
Original Assignee
VG Life Sciences Inc
University of Colorado
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VG Life Sciences Inc, University of Colorado filed Critical VG Life Sciences Inc
Priority to EP13155864.5A priority Critical patent/EP2633864A1/de
Publication of EP2323679A2 publication Critical patent/EP2323679A2/de
Publication of EP2323679A4 publication Critical patent/EP2323679A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
EP09800699A 2008-07-25 2009-07-23 Clip-hemmer und verfahren zur modulierung der immunfunktion Withdrawn EP2323679A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13155864.5A EP2633864A1 (de) 2008-07-25 2009-07-23 Clip-Hemmer und Verfahren zur Modulation der Immunfunktion

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13594208P 2008-07-25 2008-07-25
PCT/US2009/004328 WO2010011347A2 (en) 2008-07-25 2009-07-23 Clip inhibitors and methods of modulating immune function

Publications (2)

Publication Number Publication Date
EP2323679A2 EP2323679A2 (de) 2011-05-25
EP2323679A4 true EP2323679A4 (de) 2012-08-22

Family

ID=41570789

Family Applications (2)

Application Number Title Priority Date Filing Date
EP13155864.5A Withdrawn EP2633864A1 (de) 2008-07-25 2009-07-23 Clip-Hemmer und Verfahren zur Modulation der Immunfunktion
EP09800699A Withdrawn EP2323679A4 (de) 2008-07-25 2009-07-23 Clip-hemmer und verfahren zur modulierung der immunfunktion

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP13155864.5A Withdrawn EP2633864A1 (de) 2008-07-25 2009-07-23 Clip-Hemmer und Verfahren zur Modulation der Immunfunktion

Country Status (4)

Country Link
EP (2) EP2633864A1 (de)
AU (1) AU2009274512A1 (de)
CA (1) CA2737146A1 (de)
WO (1) WO2010011347A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015035414A1 (en) * 2013-09-09 2015-03-12 The Texas A&M University System Treating neurological disorders
EP3517117A1 (de) * 2018-01-30 2019-07-31 Medizinische Universität Wien Arzneimittel zur vorbeugung oder behandlung von rhinovirusinfektionen
US20230226135A9 (en) * 2019-07-19 2023-07-20 Bcell Solutions, Inc. Acetylcholine modulation of immune function
EP3818989A1 (de) * 2020-03-12 2021-05-12 Universität Greifswald Peptide und oligonukleotide für einen sars-cov-2-impfstoff

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043361A2 (en) * 2002-11-08 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
WO2005079523A2 (en) * 2004-02-18 2005-09-01 University Of Georgia Research Foundation, Inc. Novel teleost derived antimicrobal polypeptides
WO2009055005A2 (en) * 2007-10-23 2009-04-30 The Regents Of The University Of Colorado Competitive inhibitors of invariant chain expression and/or ectopic clip binding

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US565354A (en) 1896-08-04 James h
US1164308A (en) 1914-11-02 1915-12-14 Nils Nilson Traction-plow.
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4415553A (en) 1973-08-06 1983-11-15 Dso "Pharmachim" Compositions, processes for their preparation and method for treatment of neoplasms
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5520914A (en) 1987-08-06 1996-05-28 President And Fellows Of Harvard College Antibodies to angiogenin: immunotherapeutic agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991003162A1 (en) 1989-08-31 1991-03-21 City Of Hope Chimeric dna-rna catalytic sequences
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5972922A (en) 1990-06-11 1999-10-26 Alcon Laboratories, Inc. Steroids which inhibit angiogenesis
JP3257675B2 (ja) 1990-10-12 2002-02-18 マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ビッセンシャフテン エー．ファウ． 修飾リボザイム
DE4216134A1 (de) 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetische katalytische oligonukleotidstrukturen
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
WO1993016177A1 (en) 1992-02-11 1993-08-19 Cell Genesys, Inc. Homogenotization of gene-targeting events
NZ254646A (en) 1992-08-19 1997-06-24 Merrell Dow Pharma Inhibition of angiogenesis by administration of a polyamide and a polyurea
EP0752248B1 (de) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
US5792771A (en) 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
NO941135L (no) 1993-04-01 1994-10-03 Daiichi Seiyaku Co Tiazolpyrimidin derivater
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US5539094A (en) 1993-11-12 1996-07-23 La Jolla Cancer Research Foundation DNA encoding Bcl-2-associated proteins
GB9326136D0 (en) 1993-12-22 1994-02-23 Erba Carlo Spa Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
JPH09507487A (ja) 1994-01-05 1997-07-29 アーキュール，インコーポレーテッド 選ばれた性質を有するアミンイミドおよびオキサゾロンをベースとした分子の系統的モジュール製造
US5583034A (en) 1994-02-22 1996-12-10 La Jolla Institute For Allergy And Immunology Enhancement of adoptosis using antisense oligonucleotides
WO1995024929A2 (en) 1994-03-15 1995-09-21 Brown University Research Foundation Polymeric gene delivery system
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5618925A (en) 1994-04-28 1997-04-08 Les Laboratories Aeterna Inc. Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression; process of making thereof
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5716824A (en) 1995-04-20 1998-02-10 Ribozyme Pharmaceuticals, Inc. 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
US5712171A (en) 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array
US5696092A (en) 1995-03-07 1997-12-09 George Washington University Methods and compositions for inhibiting metastasis of epithelial cell-derived cancers
US7625565B2 (en) 1995-05-01 2009-12-01 Viral Genetics, Inc. Antiviral compositions comprising lysine-rich histone fractions prepared by pepsin treatment of thymic cell nuclei
US5639757A (en) 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
AU7690896A (en) * 1995-09-14 1997-04-01 Universitat Tubingen Recombinant polypeptide based on the primary sequence of the invariant chain with at least one primary sequence of a specific t-cell epitope or a protein derivative and nucleic acids coding for this recombinant polypeptide
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
AU1087797A (en) * 1996-01-03 1997-08-01 Australian National University, The Clip analogues and autoimmune disease
CA2253382A1 (en) 1996-01-16 1997-07-24 Ribozyme Pharmaceuticals, Inc. Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules
US6750044B1 (en) 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043361A2 (en) * 2002-11-08 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
WO2005079523A2 (en) * 2004-02-18 2005-09-01 University Of Georgia Research Foundation, Inc. Novel teleost derived antimicrobal polypeptides
WO2009055005A2 (en) * 2007-10-23 2009-04-30 The Regents Of The University Of Colorado Competitive inhibitors of invariant chain expression and/or ectopic clip binding

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ADAMS SHARLENE ET AL: "Biological activity and therapeutic potential of homologs of an Ii peptide which regulates antigenic peptide binding to cell surface MHC class II molecules", ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH, ECV EDITIO CANTOR VERLAG, AULENDORF, DE, vol. 47, no. 9, 1 January 1997 (1997-01-01), pages 1069 - 1077, XP001526055, ISSN: 0004-4172 *
CHRISTIE G ET AL: "Alzheimer's disease: correlation of the suppression of.beta.-amyloid peptide secretion from cultured cells with inhibition of the chymotrypsin-like activity of the proteasome", JOURNAL OF NEUROCHEMISTRY, WILEY INTERSCIENCE, NEW YORK, NY, US, vol. 73, no. 1, 1 January 1999 (1999-01-01), pages 195 - 204, XP002209921, ISSN: 0022-3042, DOI: 10.1046/J.1471-4159.1999.0730195.X *
HILLMAN G G ET AL: "Generating MHC Class II+/Ii- phenotype after adenoviral delivery of both an expressible gene for MHC Class II inducer and an antisense Ii-RNA construct in tumor cells", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 10, no. 17, 1 August 2003 (2003-08-01), pages 1512 - 1518, XP009160950, ISSN: 0969-7128 *
HITZEL CHRISTOPH ET AL: "The invariant chain derived fragment clip is an efficient in vitro inhibitor of peptide binding to MHC class II molecules", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 33, no. 1, 1 January 1996 (1996-01-01), pages 25 - 31, XP009160759, ISSN: 0161-5890, [retrieved on 19990426], DOI: 10.1016/0161-5890(95)00131-X *
LU XUEQING ET AL: "Suppression of major histocompatibility complex class II-associated invariant chain enhances the potency of an HIV gp120 DNA vaccine", IMMUNOLOGY, BLACKWELL PUBLISHING, OXFORD, GB, vol. 120, no. 2, 1 February 2007 (2007-02-01), pages 207 - 216, XP002612403, ISSN: 0019-2805, DOI: 10.1111/J.1365-2567.2006.02492.X *
STEIN R ET AL: "CD74: A new candidate target for the immunotherapy of B-cell neoplasms", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 13, no. 18, 15 September 2007 (2007-09-15), pages 5556S - 5563S, XP002510850, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-07-1167 *
WU S ET AL: "The MHC class II-associated invariant chain-derived peptide CLIP binds to the peptide-binding groove of class II molecules", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 33, no. 4-5, 1 March 1996 (1996-03-01), pages 371 - 377, XP027285074, ISSN: 0161-5890, [retrieved on 19960301] *
XU MINZHEN ET AL: "Immunotherapy of cancer by antisense inhibition of Ii protein, an immunoregulator of antigen selection by MHC class II molecules", CURRENT OPINION IN MOLECULAR THERAPEUTICS, CURRENT DRUGS, LONDON, GB, vol. 6, no. 2, 1 April 2004 (2004-04-01), pages 160 - 165, XP009115265, ISSN: 1464-8431 *

Also Published As

Publication number Publication date
CA2737146A1 (en) 2010-01-28
EP2323679A2 (de) 2011-05-25
AU2009274512A1 (en) 2010-01-28
WO2010011347A2 (en) 2010-01-28
WO2010011347A9 (en) 2010-04-08
EP2633864A1 (de) 2013-09-04
WO2010011347A3 (en) 2010-05-27

Similar Documents

Publication Publication Date Title
IL248723B (en) Specific antibodies against the bcr complex and methods of using them
HRP20192282T8 (hr) Inhibitori tfpi i postupci upotrebe
HK1160119A1 (en) Kinase inhibitors and methods of use
EP2252293A4 (de) Kinasehemmer und verwendungsverfahren
HK1161583A1 (en) Deacetylase inhibitors and uses thereof
LT2373691T (lt) Anti-fxi antikūnai ir jų panaudojimo būdai
EP2637502A4 (de) Mutanten-selektive egfr-hemmer und verwendungen davon
IL199969A0 (en) Methods of modulating immune function
EP2311002A4 (de) Systeme und verfahren zur visuellen darstellung von angeboten
EP2379561A4 (de) Mlk-inhibitoren und anwendungsverfahren
EP2376085A4 (de) Verbindungen und anwendungsverfahren
EP2340244A4 (de) Verbindungen und anwendungsverfahren
HK1149933A1 (en) Diazacarbazoles and methods of use
IL211623A0 (en) Anti-notch2 antibodies and methods of use
EP2344204A4 (de) Telomerasehemmer und anwendungsverfahren dafür
EP2137168A4 (de) Neue ido-inhibitoren und verfahren zu deren anwendung
IL209548A0 (en) Diazacarbazoles and methods of use
EP2291536A4 (de) Antikörper gegen psgl-1 und verfahren zur identifizierung und verwendung
EP2309938A4 (de) Kryochirurgische systeme und anwendungsverfahren dafür
EP2536709A4 (de) Prolylhydroxylasehemmer und verwendungsverfahren dafür
EP2346521A4 (de) Peptide und verwendungsverfahren dafür
EP2346425A4 (de) Modulierte einzwängungsvorrichtung und verwendungsverfahren dafür
IL213695A0 (en) Adhesive compounds and methods of use thereof
EP2379076A4 (de) Phosphodiesterase-hemmer und ihre verwendungen
EP2323679A4 (de) Clip-hemmer und verfahren zur modulierung der immunfunktion

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110225

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1158107

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20120724

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/08 20060101AFI20120718BHEP

Ipc: A61P 33/06 20060101ALI20120718BHEP

Ipc: A61P 31/18 20060101ALI20120718BHEP

Ipc: A61K 33/06 20060101ALI20120718BHEP

Ipc: A61P 37/08 20060101ALI20120718BHEP

Ipc: A61P 1/16 20060101ALI20120718BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130221

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1158107

Country of ref document: HK